Asensus Surgical

Asensus Surgical is revolutionizing minimally invasive surgery by developing and commercializing the Senhance® Surgical System, a robotic platform integrated with the first globally approved intra-operative augmented intelligence system. The company focuses on reducing surgical variability, improving surgeon ergonomics, and increasing accessibility through reusable instruments and a lower-cost model. Following its acquisition by KARL STORZ, Asensus is positioned to accelerate the global adoption of its digital surgery technology, aiming to set a new standard of care in robotic-assisted procedures.

The Senhance® Surgical System is a robotic-assisted laparoscopic platform integrated with the Intelligent Surgical Unit™ (ISU™), an augmented intelligence engine that provides real-time surgical guidance and insights to improve precision and decision-making.

Total raised: $337M

Primary competitor is Intuitive Surgical (da Vinci). Asensus differentiates through augmented intelligence (ISU), reusable instruments for lower cost-per-procedure, haptic feedback, and an open console design. Its integration into KARL STORZ's ecosystem provides a formidable distribution advantage against other newer entrants like Medtronic, J&J, and CMR Surgical.